Chelation therapy can include chemicals like such as:

• DSMA (dimercaptosuccinic acid)

• EDTA ( Ethylenediaminetetraacetic acid)

• Dimercaprol

• Penicillamine

Some are given IV and others orally.

Heavy metals or aluminium in the body causing harm and disrupting development.

Chelators bind to these heavy metals and aluminium.

They make it easier for the liver and kidneys to clear it from the body typically via urine or fecaes.

It then leaves the body with studies showing it has helped improve autism symptoms such as....

How chelation works

How to used chelation therapy

Pros

• Behavioral Benefits: DMSA therapy, especially the 7-round treatment, was associated with significant improvements in behavioral symptoms of autism across multiple assessment tools (ATEC, PDD-BI, SAS, ADOS, PGI).

• Biological Correlation: Improvements in the 7-round group were strongly linked to the excretion of toxic metals and changes in glutathione levels, providing evidence of a biological mechanism rather than a placebo effect.

• Safety Profile: The therapy was generally safe, with no significant adverse effects on gut function or other areas, except for a slight, often temporary increase in hyperactivity in some cases. DMSA is also FDA-approved for lead poisoning, supporting its established safety record.

• Age Inclusivity: Benefits were observed across a range of ages, making it potentially applicable to both younger and older children with ASD.

Cons

• Study Design Limitations: The study was not a true placebo-controlled trial because the initial screening round in Phase 1 affected glutathione and platelet levels, potentially influencing subsequent results and complicating interpretation.

• Unclear Dosage and Duration: The exact dose and total treatment duration are not specified in this document, limiting the ability to replicate or apply the findings clinically without additional information.

• Mixed Outcomes: Approximately 11% of participants experienced a slight worsening of symptoms, and some showed temporary hyperactivity, indicating that the therapy may not benefit all children equally.

• Limited Additional Benefit: The 7-round group did not show significantly greater improvements than the 1-round group, raising questions about the necessity or added value of multiple rounds.

• Need for Further Research: Longer-term studies are required to assess whether extended treatment yields greater benefits and to confirm the findings in a more controlled setting

[CH 1]

Pros

• Behavioral Gains: Significant reductions in autism severity, particularly in sociability, cognitive awareness, and behavior, as measured by ATEC.

• Hyperandrogenemia Relief: Effective reduction of symptoms like early puberty and aggression.

• Safety: Minimal impact on essential minerals and organ function; prior studies suggest Lupron is safe long-term for reproductive health.

• Biological Effects: Confirmed reductions in androgen levels and increased heavy metal excretion, supporting the treatment’s mechanism.

• Quick Response: Some improvements observed within days of starting Lupron.

Cons

• Small Sample Size: Only 11 children, limiting the ability to generalize findings.

• No Control Group: The open-label design raises questions about whether improvements were due to the treatment or other factors (e.g., placebo effect).

• Side Effects: Gastrointestinal disturbances in some cases, though manageable with transdermal DMSA.

• Unknown Long-Term Effects: While short-term safety was shown, long-term impacts (e.g., on reproduction) remain unstudied in this context.

• Complexity: Multiple medications and administration routes may pose logistical challenges for families.

[CH 2]

Pros

• Comprehensive Approach: The treatment addressed multiple factors (nutrition, environment, chelation, and therapies), potentially offering a holistic benefit.

• Significant Improvements: All 10 children showed progress in behavior, social skills, and academic abilities, with some returning to regular classrooms.

• Reduction in Heavy Metal Burden: The significant drop in urinary lead levels suggests effective detoxification, which may correlate with clinical improvements.

Cons

• Small Sample Size: Only 10 patients were included, limiting the generalizability of the findings.

• Lack of Control Group: Without a control group, it’s unclear whether improvements were due to the treatment, ongoing therapies, or natural development.

• Not Randomized or Blinded: The open-label design increases the risk of bias from parents, teachers, or clinicians.

• Lack of Specific Details: The absence of exact chelator doses and precise timelines for symptom improvement hinders replication and interpretation.

• Multifaceted Treatment: The use of multiple interventions simultaneously makes it difficult to determine which component (e.g., chelation, nutrition, or therapy) drove the observed effects.

[CH 3]